Biomarker testing in HIPEC plus immunotherapy for gastric peritoneal spread
Part of Cancer, Digestive system clinical trials.
This study checks blood and tissue biomarkers in people with advanced gastric cancer that has spread to the lining of the abdomen. It looks at patients who have already had HIPEC plus a PD-1/PD-L1 antibody treatment, to better understand response and eligibility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed advanced gastric (or gastroesophageal junction) adenocarcinoma on pathology testing
- You are between 18 and 75 years old (and if pregnant, you must not be; otherwise follow the trial’s consent rules)
- Your day-to-day functioning is very good: ECOG score 0 to 1
- Your tumor tests negative for HER2 (checked by a lab test such as immunocytochemistry or FISH)
- Your cancer has spread to the abdominal lining (peritoneal metastasis) confirmed during laparoscopy, with PCI 20 or lower
- You have already received conversion treatment with HIPEC combined with a PD-1/PD-L1 inhibitor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This Phase 2 trial studies a combination treatment for stomach (or stomach-to-esophagus) cancer that has spread to the belly lining. It tests whether adding the immunotherapy drug sintilimab to a procedure called HIPEC can improve outcomes for people who have not had prior treatment.
This trial tests a treatment called HIPEC done during/around surgery after chemotherapy for advanced stomach (gastric) cancer. It may help patients live longer or have fewer cancer-related problems after the operation.
This study tests whether a specialized surgery called HIPEC (heat-treated chemotherapy placed in the belly) can improve outcomes for people with advanced stomach cancer that has reached the lining of the abdomen. It’s given after you’ve already had standard chemotherapy, aiming to better control disease in the belly.
This trial tests if adding heated chemotherapy (HIPEC) right after stomach cancer surgery can help people with locally advanced gastric cancer live longer. It's for patients whose cancer has not spread to other parts of the body and who are fit enough for major surgery.
This trial compares standard laparoscopic surgery for stomach cancer versus the same surgery plus HIPEC, which is heated chemotherapy placed in the abdomen during the operation. It aims to see if adding the heated chemotherapy improves outcomes for people with higher-stage stomach cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.